Therapeutics and Clinical Risk Management
The advent of exponential growth of novel agents tested and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has brought about a need for understanding of the mechanism of action, side-effects, and clinical efficacy of these drugs as they relate to these patients. This review will provide a synopsis of the treatment landscape in mCRPC as varying agents such as abiraterone acetate, cabazitaxel, sipuleucel-T, radium, and selected emerging agents are presented. A distinct focus on the utilization of enzalutamide, its mechanism of action, key pivotal trials that brought about its US Food and Drug Administration approval, as well as patient-focused perspectives and clinical implications are discussed herein.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License
Patel, N.K., Finianos, A., Whitaker, K.D., Aragon-Ching, J.B. (2014). Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies. Therapeutics and Clinical Risk Management, 10, 651-664.